Methylprednisolone Completed Phase 4 Trials for Disseminated Sclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00753792Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse
NCT01986998Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse